Medicare recipients may get obesity drugs for just $149 a month under a reported White House deal in the works
1. A White House deal may cut obesity drug prices to $149/month. 2. Medicare might extend coverage for GLP-1 drugs to high-risk obese individuals. 3. GLP-1 drugs like Ozempic and Wegovy are currently not covered for obesity. 4. Novo Nordisk aims to improve patient access and affordability for medications. 5. Concerns exist regarding the safety of GLP-1 drugs for older adults.